Notably, the association of early clearance of plasma EBV DNA with clinical outcome in RM-NPC patients treated with anti-PD-1 immunotherapy was positive in POLARIS-02 and CAPTAIN-1st trials but negative in the Mayo Clinic Phase 2 Consortium study of nivolumab [3, 5, 19, 20]. This evidence concerns the gene PDCD1 and nasopharyngeal carcinoma.